These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18600598)

  • 21. Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
    Cao S; Abraham A; Nair MG; Pati R; Galivan JH; Hausheer FH; Rustum YM
    Clin Cancer Res; 1996 Apr; 2(4):707-12. PubMed ID: 9816221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.
    Izbicka E; Diaz A; Streeper R; Wick M; Campos D; Steffen R; Saunders M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):993-9. PubMed ID: 19221750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
    Serova M; Bieche I; Sablin MP; Pronk GJ; Vidaud M; Cvitkovic E; Faivre S; Raymond E
    Br J Cancer; 2011 Jan; 104(2):272-80. PubMed ID: 21179031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma.
    Toner LE; Vrhovac R; Smith EA; Gardner J; Heaney M; Gonen M; Teruya-Feldstein J; Sirotnak F; O'Connor OA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):924-32. PubMed ID: 16467107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.
    Sirotnak FM; Schmid FA; Samuels LL; DeGraw JI
    NCI Monogr; 1987; (5):127-31. PubMed ID: 2448650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
    O'Connor OA; Hamlin PA; Portlock C; Moskowitz CH; Noy A; Straus DJ; Macgregor-Cortelli B; Neylon E; Sarasohn D; Dumetrescu O; Mould DR; Fleischer M; Zelenetz AD; Sirotnak F; Horwitz S
    Br J Haematol; 2007 Nov; 139(3):425-8. PubMed ID: 17910632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs.
    McGuire JJ; Haile WH
    Biochem Pharmacol; 2009 Apr; 77(7):1161-72. PubMed ID: 19174154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.
    Ho AL; Lipson BL; Sherman EJ; Xiao H; Fury MG; Apollo A; Seetharamu N; Sima CS; Haque S; Lyo JK; Sales R; Cox L; Pfister DG
    Invest New Drugs; 2014 Jun; 32(3):549-54. PubMed ID: 24566705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.
    Visentin M; Unal ES; Zhao R; Goldman ID
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):597-606. PubMed ID: 23881211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
    O'Connor OA; Horwitz S; Hamlin P; Portlock C; Moskowitz CH; Sarasohn D; Neylon E; Mastrella J; Hamelers R; Macgregor-Cortelli B; Patterson M; Seshan VE; Sirotnak F; Fleisher M; Mould DR; Saunders M; Zelenetz AD
    J Clin Oncol; 2009 Sep; 27(26):4357-64. PubMed ID: 19652067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions.
    Marneros AG; Grossman ME; Silvers DN; Husain S; Nuovo GJ; MacGregor-Cortelli B; Neylon E; Patterson M; O'Connor OA; Zain JM
    Blood; 2009 Jun; 113(25):6338-41. PubMed ID: 19389878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
    O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
    J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind.
    Altınay S; Kural A; Özmen A; Tural D; Tutar Y
    Anticancer Agents Med Chem; 2023; 23(3):298-305. PubMed ID: 35692151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions.
    McPherson JP; Vrontikis A; Sedillo C; Halwani AS; Gilreath JA
    Pharmacotherapy; 2016 Feb; 36(2):e8-e11. PubMed ID: 26809959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular basis of antifolate resistance.
    Assaraf YG
    Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Jennifer C Z; Sara Mohamed J; Salma A; Francine F
    Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro.
    Visentin M; Unal ES; Goldman ID
    Cancer Chemother Pharmacol; 2014 May; 73(5):1055-62. PubMed ID: 24682532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.
    Wang ES; O'Connor O; She Y; Zelenetz AD; Sirotnak FM; Moore MA
    Leuk Lymphoma; 2003 Jun; 44(6):1027-35. PubMed ID: 12854905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.